Abvc Biopharma, Inc.

ABVC

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001173313


None

No letter

5 of 14 inputs computable; 7 are required, with a score in every sleeve


Scoreboard	
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $21.1M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	late filer, thin data not computable: dilution, short runway, distress, fortress balance sheet
Inputs computable	5 of 14
Graded from	filings received through Mar 3, 2026 244 days before the rescan; latest periodic filing 10-Q received Aug 12, 2026
Last close	$1.05 2026-10-29; market equity $0; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 3, 2026

breakthrough products and technologies to combat various diseases through efficient industrial manufacturing. Biotechnology is an important business sector in the world's economies and is vital to human health. Companies engaged in biotechnology generally require large amounts of capital investment for their research & development activities. Developing and commercializing a new drug or medical device may take up to tens of years. ABVC ("we" or the "Company") is an early-stage biotechnology company with a pipeline of seven new drugs and one medical device under development, all of which are licensed from related parties of the Company.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 12.2						
Gross profitability	not computable	32.4%				

latest aligned inputs end 2024-12-31; latest annual assets end 2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Return on invested capital	not computable	9.3%			
one or more required annual facts are missing					
Accruals ratio	(34.4%)	(6.6%)	12.2	803	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
latest aligned inputs end 2024-12-31; latest annual assets end 2025-12-31					
Solvency, sleeve percentile 81.8					
Twelve-month failure probability	not computable	0.08%			
firm-wide XBRL shares cannot be assigned to one ticker class					
Altman Z double-prime	(13.82)	(0.35)	68.0	748	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
interest expense must exceed $100,000					
Current ratio	0.41x	2.92x	95.5	829	2025-12-31
Growth and financing, sleeve percentile 53.8					
Revenue growth, three-year compound	(32.7%)	10.1%	92.2	412	2025-12-31
Free cash flow growth, three-year compound	not computable	10.9%			
four consecutive annual FCF observations are required; found 4					
Reinvestment rate	not computable	37.1%			
pretax income must exceed the validity floor and imply a 0%-100% tax rate					
Asset growth, three years	30.0%	2.2%	15.4	696	2025-12-31
Net share issuance, one year	not computable	2.5%			
firm-wide XBRL shares cannot be assigned to one ticker class					

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Late filer	found 2 NT 10-K/Q filings in the last eight quarters
Thin data	5 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-10-29 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(62.1%)	(2.2%)	10
Distance from 52-week high	(66.6%)	(28.7%)	15
EBIT to enterprise value	not computable	(1.4%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	not computable	0.28	
Sales to price	not computable	0.30	
Composite equity issuance, five years	not computable	20.5%	
Relative strength against the sector, log excess return	(1.14)	(0.19)	10

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail

Cash, filings, liquidity

Cash and equivalents	$31,944
Operating cash flow, four quarters	-$2.7M
Months of runway	not finite
Days since last periodic filing	82 (10-Q received Aug 12, 2026)
Median daily dollar volume, 63 sessions	$91,061

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$508,826	2024-12-31	2026-03-03	10-K	26-023063
2	assets	us-gaap:Assets	$7.5M	2024-12-31	2026-03-03	10-K	26-023063
3	net income	us-gaap:NetIncomeLoss	-$7.9M	2025-12-31	2026-03-03	10-K	26-023063
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$3.0M	2025-12-31	2026-03-03	10-K	26-023063
5	assets	us-gaap:Assets	$21.1M	2025-12-31	2026-03-03	10-K	26-023063
6	revenue	us-gaap:Revenues	$509,589	2024-12-31	2026-03-03	10-K	26-023063
7	gross profit	us-gaap:GrossProfit	-$149,607	2023-12-31	2025-04-15	10-K	25-032118
8	revenue	us-gaap:Revenues	$152,430	2023-12-31	2025-04-15	10-K	25-032118
9	gross profit	us-gaap:GrossProfit	$683,368	2022-12-31	2024-03-13	10-K	24-022235
10	revenue	us-gaap:Revenues	$969,783	2022-12-31	2024-03-13	10-K	24-022235
11	gross profit	us-gaap:GrossProfit	$350,711	2021-12-31	2023-03-31	10-K	23-025554
12	revenue	us-gaap:Revenues	$355,797	2021-12-31	2023-03-31	10-K	23-025554
13	gross profit	us-gaap:GrossProfit	$464,329	2020-12-31	2022-03-31	10-K	22-016726
14	revenue	us-gaap:Revenues	$483,045	2020-12-31	2022-03-31	10-K	22-016726
15	current assets	us-gaap:AssetsCurrent	$2.5M	2025-12-31	2026-03-03	10-K	26-023063
16	current liabilities	us-gaap:LiabilitiesCurrent	$6.2M	2025-12-31	2026-03-03	10-K	26-023063
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$76.9M	2025-12-31	2026-03-03	10-K	26-023063
18	operating income	us-gaap:OperatingIncomeLoss	-$7.2M	2025-12-31	2026-03-03	10-K	26-023063
19	book equity	us-gaap:StockholdersEquity	$11.1M	2025-12-31	2026-03-03	10-K	26-023063
20	liabilities	us-gaap:Liabilities	$7.8M	2025-12-31	2026-03-03	10-K	26-023063
21	operating income	us-gaap:OperatingIncomeLoss	-$6.8M	2023-12-31	2025-04-15	10-K	25-032118
22	interest expense	us-gaap:InterestAndDebtExpense	$20,094	2023-12-31	2024-03-13	10-K	24-022235
23	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAs...	$296,000	2025-12-31	2026-03-03	10-K	26-023063
24	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$21,201	2023-12-31	2025-04-15	10-K	25-032118
25	depreciation amortization	us-gaap:Depreciation	$28,531	2023-12-31	2025-04-15	10-K	25-032118
26	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$8.0M	2023-12-31	2025-04-15	10-K	25-032118
27	income tax	us-gaap:IncomeTaxExpenseBenefit	$256,006	2023-12-31	2025-04-15	10-K	25-032118
28	current assets	us-gaap:AssetsCurrent	$1.7M	2023-12-31	2025-04-15	10-K	25-032118
29	current liabilities	us-gaap:LiabilitiesCurrent	$6.1M	2023-12-31	2025-04-15	10-K	25-032118
30	current assets	us-gaap:AssetsCurrent	$3.0M	2022-12-31	2024-03-13	10-K	24-022235
31	current liabilities	us-gaap:LiabilitiesCurrent	$5.5M	2022-12-31	2024-03-13	10-K	24-022235
32	assets	us-gaap:Assets	$7.8M	2023-12-31	2025-04-15	10-K	25-032118
33	assets	us-gaap:Assets	$9.6M	2022-12-31	2024-03-13	10-K	24-022235

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.